Alnylam Pharmaceuticalsvs.Incyte
ALNY vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 1.7× larger than Incyte by market cap; Incyte trades at the lower P/E (16.1 vs 69.1); year to date, Incyte leads (+18.2% vs −24.9%).
Side by side
| ALNY | INCY | |
|---|---|---|
| Market cap | $39.9B | $23.1B |
| Price | $298.76 | $116.71 |
| Today | −4.5% | −1.5% |
| Return YTD | −24.9% | +18.2% |
| Return 1Y | −7.4% | +65.9% |
| P/E | 69.1 | 16.1 |
| P/S | 9.3 | 4.3 |
| P/B | 37.1 | 4.1 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Pioneer of RNAi medicines for rare and cardiovascular diseases.
Full ALNY profile →More comparisons in Biotech & innovation
See where ALNY and INCY sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →